Merck’s reported interest in MoonLake Immunotherapeutics fits with the company’s approach to dealmaking.\n Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 billion to buy MoonLake Immunotherapeutics to add an inflammatory disease prospect to its late-phase pipeline. The Financial Times reports Merck submitted a nonbinding offer that valued MoonLake at more than $3 billion earlier this year. The offer

Evaxion awarded a grant from the Gates FoundationGrant funds research aimed at ultimately eradicating polio, a highly infectious viral diseaseEvaxion will apply its leading AI-Immunology™ platform to identify and combine various antigens to combat the virus and develop design options for a potential new vaccine constructRisk of a global polio resurgence and health crisis remain, thus a new vaccine concept is warrantedCOPENHAGEN, Denmark, June 3, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a c

Expanded IP Portfolio Enhances Data Harmonization and Predictive Analytics Capabilities for High-Growth Biomedical Markets LOS ANGELES, June 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a clinical-stage precision medicine company, today announced that its subsidiary BioSymetrics has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application titled “Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Pre

LOS ANGELES, June 03, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, today announced it entered an exclusive, worldwide licensing agreement with the University of California, Los Angeles (UCLA). The license expands Trethera’s intellectual property (IP) estate for TRE-515, its lead deoxycytidine kinase (dCK) inhibitor, to include new therapeutic uses in autoimmune and

Drug development grant will advance 10 physician-scientists' discoveries toward the clinic CLEVELAND, June 3, 2025 /PRNewswire/ -- Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, today announced the 2025 class of Harrington Scholar-Innovators. The scholar awards will support breakthrough new treatments for common and rare diseases, including cardiovascular, inflammatory and infectious diseases and cancer, using small molecule, nucleic acid, cell-based, and genetic ther

BEVERLY HILLS, Calif., June 3, 2025 /PRNewswire/ -- Buscar Company (OTC: CGLD), a publicly traded diversified holding company headquartered in Beverly Hills, California, is thrilled to announce the acquisition of a 70% stake in Armorgenix Company through a strategic stock swap. This transformative acquisition marks a significant expansion of Buscar's portfolio into the pharmaceutical sector, complementing its established operations in natural resources and sustainable technologies. Armorgenix's

Nearly half of uninsured Spanish speakers are unfamiliar with prescription discount cards – a gap that’s putting affordable medications out of reach for millionsESTERO, Fla., June 03, 2025 (GLOBE NEWSWIRE) -- Visory Health, a patient-first health tech prescription platform that is transforming the way Veterans, families, and caregivers access affordable healthcare through its prescription discount card, today released new survey findings detailing the critical need for prescription savings amo

SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced two oral presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress, taking place June 13-16, 2025, in Glasgow, United Kingdom and virtually. The present

NEW ORLEANS, June 3, 2025 /PRNewswire/ -- Nest Health, the leading family-centered, home-based healthcare provider for high-risk families, today announced the launch of Nest Rooted Recovery, a new Medication for Opioid Use Disorder (MOUD) program. The program brings evidence-based addiction treatment into the home while integrating ongoing medical, behavioral, and social care for the entire family. Unlike traditional programs addressing substance use disorder or mental health in isolation, Nest

Company enters option agreement with JiKang Therapeutics to in-license novel APJ agonist antibody New composition of matter IP filed for chemically distinct, orally active, and highly potent small molecule APJ agonists EMERYVILLE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced advances in its a